Myosin Therapeutics Inc. is thrilled to announce a successful funding round that secured $3,000,000 to propel its groundbreaking research and development efforts forward. As the first nanomotor platform company focused on oncology, Myosin Therapeutics is pioneering novel pharmacotherapies targeting members of the myosin family of molecular motors. The infusion of capital will primarily support the advancement of the proprietary nMotor system—a full screening platform that spans high-throughput screening (HTS), validation, and target selectivity profiling. This robust platform underpins the company’s innovative approach to developing a diverse pipeline of oncology therapeutics, including a unique treatment aimed at improving outcomes in Glioblastoma (GBM). With GBM representing a critical unmet need in oncology and a significant serviceable market with an estimated 10,000 cases annually in the US alone, the potential impact of this therapeutic is immense.
In addition to its oncology initiatives, Myosin Therapeutics is breaking new ground in neurotherapeutics by developing a novel treatment to prevent relapse in METH use disorder—a chronic condition currently lacking FDA-approved medication. The funding will also empower comprehensive preclinical studies exploring the application of first-in-class pharmacotherapeutics targeting NMII in varied domains, including other substance use disorders, neural regeneration, and infectious diseases. Moreover, the approval of a clinically safe NMII inhibitor could open new avenues for research into the fundamental roles of NMII in human physiology, such as learning and memory. With this new investment, Myosin Therapeutics is well-positioned to accelerate its mission of delivering innovative treatments that improve health outcomes and address critical unmet medical needs.
